A role for Biofoundries in rapid development and validation of automated SARS-CoV-2 clinical diagnostics

Abstract

The SARS-CoV-2 pandemic has created large demand on global testing capability. Here the authors use the London Biofoundry, an automated synthetic biology platform, and develop an open-source virus-like particle to implement high-throughput diagnostics.